atorvastatin pensa 10 mg
pensa pharma ab - atorvastatinkalsiumtrihydrat - tablett, filmdrasjert - 10 mg
atorvastatin pensa 20 mg
pensa pharma ab - atorvastatinkalsiumtrihydrat - tablett, filmdrasjert - 20 mg
atorvastatin pensa 40 mg
pensa pharma ab - atorvastatinkalsiumtrihydrat - tablett, filmdrasjert - 40 mg
atorvastatin pensa 80 mg
pensa pharma ab - atorvastatinkalsiumtrihydrat - tablett, filmdrasjert - 80 mg
drytec tm -
ge healthcare b.v. - natriummolybdat mo-99 omdannes til natriumperteknetat tc-99m - radionuklidegenerator
teceos 13 mg
cis bio international - butedronatetetranatrium - preparasjonssett til radioaktive legemidler - 13 mg
technescan dtpa -
curium netherlands b.v. - kalsiumtrinatriumpentetat - preparasjonssett til radioaktive legemidler
technescan hdp -
curium netherlands b.v. - natriumoksidronat - preparasjonssett til radioaktive legemidler
tivicay
viiv healthcare bv - dolutegravir - hiv-infeksjoner - antivirale midler til systemisk bruk - tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg. tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 4 weeks of age or older and weighing at least 3 kg.
triumeq
viiv healthcare b.v. - dolutegravir sodium, lamivudine, abacavir (as sulfate) - hiv-infeksjoner - antivirale midler til systemisk bruk - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children weighing at least 25 kg who are antiretroviral treatment-naïve or are infected with hiv without documented or clinically suspected resistance to any of the three antiretroviral agents in triumeq.